Tango Therapeutics, Inc.
https://www.tangotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tango Therapeutics, Inc.
Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019
With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.
Gilead Decides On Bigger Dance Floor With Tango
Gilead is making a $20m equity investment in Tango, with the biotech’s series B backers also increasing their investments.
Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools